KEAP1 Modulator Crystalline Form I for Stability and Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of (R)-1-(3-(3-(4-aminopyrimidin-2-yl)-5-chlorophenyl)morpholino)prop-2-en-1-one lack stability and purity, which are crucial for effective pharmaceutical use.
Innovation Solution
The compound is crystallized under specific conditions to obtain a stable and substantially pure crystalline form I, characterized by distinct X-ray powder diffraction peaks and thermal properties, suitable for pharmaceutical processing and storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing formulations are used, then the compound can be processed, but stability and purity are insufficient for pharmaceutical use
Solution Approach 1:
The patent applies parameter changes by optimizing crystallization conditions including solvent selection (ethanol, isopropanol, or water), temperature profiles (cooling rates from 0.1 to 10°C per hour), and pH adjustment (maintaining pH 6-8 with ammonium hydroxide). These parameter modifications transform the compound from existing unstable formulations into stable crystalline forms with ≥98% purity, resolving the contradiction between stability and purity requirements for pharmaceutical use
Solution Approach 2:
The patent utilizes phase transitions through controlled crystallization processes where the compound transitions from solution phase to solid crystalline phase. By controlling cooling rates and solvent evaporation, the patent achieves formation of stable crystalline forms with defined melting points (135-145°C) and characteristic XRD patterns, ensuring both stability during storage and high purity ≥98% free from amorphous or alternative crystalline forms
2Reliability
If the compound is crystallized under specific conditions, then stability and purity are improved, but processing complexity increases
Solution Approach 1:
The patent applies self-service through spontaneous crystallization where the compound automatically forms stable crystalline structures under controlled conditions without requiring complex intervention. The process uses simple equipment (reactor, filtration system, drying oven) and relies on the compound's inherent crystallization tendency when pH is maintained at 6-8 and cooling rates are controlled, reducing processing complexity while achieving ≥98% purity and stability
Solution Approach 2:
The patent simplifies processing by identifying critical parameters (solvent type, temperature, pH) and holding them within specific ranges. By using common solvents (ethanol, isopropanol, water) and standard pH adjustment with ammonium hydroxide, the patent avoids complex processing equipment while achieving stable crystalline forms with defined characteristics including melting point 135-145°C and characteristic XRD peaks, resolving the contradiction between improved reliability and processing complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline form I provides stability and purity, making it suitable for pharmaceutical formulations, ensuring consistent quality and efficacy.
Implementation Method 1
it has now been found that (R)-1-(3-(3-(4-aminopyrimidin-2-yl)-5-chlorophenyl)morpholino)prop-2-en-1-one can be obtained in a stable and substantially pure crystalline form by crystallization under certain conditions
Data Source
AI summary
The present disclosure relates to a solid crystalline form of (R)-1-(3-(3-(4-aminopyrimidin-2-yl)-5-chlorophenyl)morpholino)prop-2-en-1-one and to methods for preparing such crystalline form. (R)-1-(3-(3-(4-aminopyrimidin-2-yl)-5-chlorophenyl)morpholino)prop-2-en-1-one is a potent KEAP1 modulator.